Search Results 531-540 of 17375 for alopecia

1. A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial - Mayo Clinic

   Patient must have recovered from any adverse events due to prior anti-cancer therapy (i.e., have no residual toxicities > grade 1 with the exception of alopecia ...

2. ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies - Mayo Clinic

   Note: Subjects with Grade ≤ 2 neuropathy or Grade ≤ 2 alopecia are an exception to the latter criterion and may qualify for the study. Women who are ...

3. Study Of The Bria-IMT Regimen And CPI Vs Physicians' Choice In Advanced Metastatic Breast Cancer. (BRIA-ABC) - Mayo Clinic

   Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion ...

4. A Study of the Safety and Effectiveness of HBI-8000 with Nivolumab to Treat Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer - Mayo Clinic

   ... alopecia). Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy. Known history of testing positive for human ...

5. A Study to Assess LXH254 in Patients with Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma - Mayo Clinic

   Presence of ≥ CTCAE grade 2 toxicity (except alopecia) due to prior anti-cancer therapy. Grade 2 endocrinopathies being treated with replacement therapy ...

6. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

   Ongoing toxicity from previous anticancer therapy that has not resolved to baseline levels or to Grade 1 or less, except for alopecia,; Participants with ...

7. A Study to Evaluate Food on Gastrointestinal Toxicity and The Effect of Selumetinib in Adolescents with Neurofibromatosis Type 1 - Mayo Clinic

   − Have any other unresolved chronic toxicity with CTCAE Grade ≥ 2, except hair changes (such as alopecia or high lightening). Participants who have ...

8. Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung - Mayo Clinic

   Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. An untreated tumor growth ...

9. A Study to Evaluate AZD1775 in Women with Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma - Mayo Clinic

   investigator. 2. With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events ...

10. A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies - Mayo Clinic

    Grade 2 neuropathy or alopecia;; For the monotherapy cohorts: Grade 2 immune-related endocrinopathy attributed to a checkpoint inhibitor and controlled with ...